Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Clin Nutr ESPEN ; 43: 197-199, 2021 06.
Article in English | MEDLINE | ID: covidwho-1135287

ABSTRACT

The COVID-19 pandemic as the largest global public health crisis is now considered as an emergency at the World Health Organization (WHO). As there is no specific therapy for SARS-CoV-2 infection at present and also because of the long time it takes to discover a new drug and the urgent need to respond urgently to a pandemic infection. Perhaps the best way right now is to find an FDA-approved drug to treat this infection. Oxidative stress and inflammation play a vital role in the progression of tissue injury in COVID-19 patients; furthermore, the G6PD activation is related to increased oxidative inflammation in acute pulmonary injury. In this regard, we propose a new insight that may be a good strategy for this urgency. Exploiting G6PD through inhibiting G6PD activity by modifying redox balance, metabolic switching and protein-protein interactions can be proposed as a new approach to improving patients in severe stage of COVID 19 through various mechanisms. Polydatin is isolated from many plants such as Polygonum, peanuts, grapes, red wines and many daily diets that can be used in severe stage of COVID-19 as a G6PD inhibitor. Furthermore, polydatin possesses various biological activities such as anti-inflammatory, antioxidant, immunoregulatory, nephroprotective, hepatoprotective, anti-arrhythmic and anti-tumor. Our hypothesis is that the consumption of antioxidants such as Polydatin (a glucoside of resveratrol) as a complementary therapeutic approach may be effective in reducing oxidative stress and inflammation in patients with COVID-19.


Subject(s)
Antioxidants/therapeutic use , COVID-19 Drug Treatment , Glucosephosphate Dehydrogenase/antagonists & inhibitors , Glucosides/therapeutic use , Phytotherapy , Plant Extracts/therapeutic use , Resveratrol/therapeutic use , Stilbenes/therapeutic use , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , COVID-19/complications , COVID-19/metabolism , Glucosides/pharmacology , Humans , Inflammation/drug therapy , Inflammation/etiology , Inflammation/metabolism , Lung/drug effects , Magnoliopsida/chemistry , Oxidative Stress/drug effects , Pandemics , Plant Extracts/pharmacology , Resveratrol/pharmacology , SARS-CoV-2 , Stilbenes/pharmacology
2.
J Anim Physiol Anim Nutr (Berl) ; 104(2): 637-644, 2020 Mar.
Article in English | MEDLINE | ID: covidwho-826338

ABSTRACT

The present study aimed to evaluate the potential therapeutic effects of Anemoside B4 (AB4), Panax notoginseng saponins (PNS), Notoginsenoside R1 (SR1), Saikosaponin A (SSA) and Saikosaponin D (SSD) on piglets infected with porcine reproductive and respiratory syndrome virus (PRRSV). A total of 132 completely healthy piglets were randomly divided into 22 groups consisting of six animals each. Control piglets were intramuscularly injected with 2 ml of PRRSV (NJGC strain) solution containing 106  TCID50  virus/ml. For low-, middle- and high-dose saponin treatment groups, the piglets were initially administrated with the same volume of PRRSV solution, followed by intraperitoneal injection with AB4, PNS, SR1, SSA or SSD at 1, 5 or 10 mg/kg b.w. on day 3. The piglets in drug control group were intraperitoneally injected with 10 mg/kg b.w. of each saponin without prior PRRS challenge, while those in blank control group were injected with the same amount of normal saline. The results indicated that all the five saponin components could decrease the incidence and severity of PRRSV-induced immunopathological damages, including the elevated body temperature, weight loss, anaemia and internal inflammation. Moreover, the saponin components could enhance protein absorption and immune responses. Taken together, this study reveals that the saponin components are effective against PRRSV infection and strengthen the immune system and thus may serve as potential antiviral therapeutic agents.


Subject(s)
Porcine Reproductive and Respiratory Syndrome/drug therapy , Saponins/therapeutic use , Animals , Blood Platelets , Drug Tapering , Erythrocyte Count , Hemoglobins , Immunoglobulin G/blood , Immunoglobulin M/blood , Leukocyte Count , Magnoliopsida/chemistry , Male , Porcine respiratory and reproductive syndrome virus , Saponins/administration & dosage , Saponins/chemistry , Swine
3.
Nutrients ; 12(9)2020 Aug 25.
Article in English | MEDLINE | ID: covidwho-731022

ABSTRACT

The 2019 novel coronavirus, SARS-CoV-2, producing the disease COVID-19 is a pathogenic virus that targets mostly the human respiratory system and also other organs. SARS-CoV-2 is a new strain that has not been previously identified in humans, however there have been previous outbreaks of different versions of the beta coronavirus including severe acute respiratory syndrome (SARS-CoV1) from 2002 to 2003 and the most recent Middle East respiratory syndrome (MERS-CoV) which was first identified in 2012. All of the above have been recognised as major pathogens that are a great threat to public health and global economies. Currently, no specific treatment for SARS-CoV-2 infection has been identified; however, certain drugs have shown apparent efficacy in viral inhibition of the disease. Natural substances such as herbs and mushrooms have previously demonstrated both great antiviral and anti-inflammatory activity. Thus, the possibilities of natural substances as effective treatments against COVID-19 may seem promising. One of the potential candidates against the SARS-CoV-2 virus may be Inonotus obliquus (IO), also known as chaga mushroom. IO commonly grows in Asia, Europe and North America and is widely used as a raw material in various medical conditions. In this review, we have evaluated the most effective herbs and mushrooms, in terms of the antiviral and anti-inflammatory effects which have been assessed in laboratory conditions.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antiviral Agents/therapeutic use , Biological Products/therapeutic use , Coronavirus Infections/drug therapy , Fungi/chemistry , Magnoliopsida/chemistry , Plants, Medicinal/chemistry , Pneumonia, Viral/drug therapy , Agaricales/chemistry , Anti-Inflammatory Agents/pharmacology , Antiviral Agents/pharmacology , Basidiomycota/chemistry , Betacoronavirus , Biological Products/pharmacology , COVID-19 , Chlorella/chemistry , Coronavirus Infections/virology , Humans , Pandemics , Phytotherapy , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Pneumonia, Viral/virology , SARS-CoV-2 , Severe Acute Respiratory Syndrome/virology , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL